Clinical Trial

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Name: A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC — clinical trial record (NCT07562581)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner

Trial Details

NCT Number	NCT07562581
Lead Sponsor	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions	Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted
Enrollment	48 participants
Start Date	2026-06
Primary Completion	2029-06 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-01